Applied Genetic Technologies Corporation (AGTC) & Its Competitors Critical Survey

Applied Genetic Technologies Corporation (NASDAQ: AGTC) is one of 282 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Applied Genetic Technologies Corporation to similar businesses based on the strength of its analyst recommendations, profitability, earnings, risk, dividends, valuation and institutional ownership.

Institutional and Insider Ownership

54.9% of Applied Genetic Technologies Corporation shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.6% of Applied Genetic Technologies Corporation shares are held by insiders. Comparatively, 17.2% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Applied Genetic Technologies Corporation and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Genetic Technologies Corporation 0 1 5 0 2.83
Applied Genetic Technologies Corporation Competitors 798 3159 11442 229 2.71

Applied Genetic Technologies Corporation presently has a consensus target price of $10.17, suggesting a potential upside of 167.54%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.18%. Given Applied Genetic Technologies Corporation’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Applied Genetic Technologies Corporation is more favorable than its competitors.

Profitability

This table compares Applied Genetic Technologies Corporation and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Applied Genetic Technologies Corporation -8.78% -2.86% -2.18%
Applied Genetic Technologies Corporation Competitors -5,571.64% -478.32% -39.78%

Risk and Volatility

Applied Genetic Technologies Corporation has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies Corporation’s competitors have a beta of 2.02, meaning that their average share price is 102% more volatile than the S&P 500.

Valuation and Earnings

This table compares Applied Genetic Technologies Corporation and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Applied Genetic Technologies Corporation $39.47 million $400,000.00 -19.00
Applied Genetic Technologies Corporation Competitors $286.20 million $34.74 million 142.71

Applied Genetic Technologies Corporation’s competitors have higher revenue and earnings than Applied Genetic Technologies Corporation. Applied Genetic Technologies Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Applied Genetic Technologies Corporation beats its competitors on 7 of the 12 factors compared.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply